Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Adds Next-Gen Sequencing Services for Biomarker Discovery, Clinical Trial Testing

Premium

AltheaDx has added next-generation sequencing services to its clinical molecular pathology laboratory for applications in cancer biomarker discovery and clinical trial testing, the company said this week.

AltheaDx CEO Francois Ferre said in a statement that next-gen sequencing will be "highly synergistic" with the company's strategy of creating cancer-specific molecular subtype panels in partnership with Compendia Bioscience. In addition, the technology will be "highly complementary" to AltheaDx's RT-PCR-based gene expression panels.

The firm plans to provide pharmaceutical and biotechnology customers with well-characterized predictive biomarker panels of genetic polymorphisms and gene expression patterns.

Based in San Diego, AltheaDx develops and tests diagnostics. The company, which has GLP- and CLIA-certified laboratories, provides clinical biomarker discovery, assay development, and validation services.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.